Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with a statin - Fasting LDL-C \>=70mg/dL and triglycerides \<=400mg/dL~Exclusion Criteria:~* Pregnant or breastfeeding females - Cardiovascular or cerebrovascular event or procedures during the past 90 days - Congestive heart failure NYHA class IV - Poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bococizumab 150mg (Type: EXPERIMENTAL): Bococizumab 150mg autoinjector (pre-filled pen)
- Bococizumab 75mg (Type: EXPERIMENTAL): Bococizumab 75mg autoinjector (pre-filled pen)
- Bococizumab 150mg placebo (Type: PLACEBO_COMPARATOR): Bococizumab 150mg placebo autoinjector (pre-filled pen)
- Bococizumab 75mg placebo (Type: PLACEBO_COMPARATOR): Bococizumab 75mg autoinjector (pre-filled pen)

Based on this trial design, predict the completion outcome and termination type (if applicable).